drugset
drugset / Trial / NCT00916110

Study Of Single Dose Of ATN-103 Administered To Healthy Japanese Male Subjects

NCT00916110 ↗

Phase 1 Completed 72 enrolled Ablynx, a Sanofi company
RandomizedParallel-groupTriple-blindTreatment

Summary

To assess the safety and tolerability of ascending single SC and IV doses of ATN-103 in healthy Japanese male subjects.

Timeline

Start
2008-11
Primary completion
2009-11
Completion
2009-11

Drugs

EvaluationDrugModalityDoseRoute
Subject OZORALIZUMAB Monoclonal antibody 1.5 mg Subcutaneous
Subject OZORALIZUMAB Monoclonal antibody 4 mg Subcutaneous
Subject OZORALIZUMAB Monoclonal antibody 10 mg Subcutaneous
Subject OZORALIZUMAB Monoclonal antibody 25 mg Subcutaneous
Subject OZORALIZUMAB Monoclonal antibody 50 mg Subcutaneous
Subject OZORALIZUMAB Monoclonal antibody 100 mg Subcutaneous
Subject OZORALIZUMAB Monoclonal antibody 200 mg Subcutaneous

Indications

No indication recorded.